{"id":"placebo-sc-q4w","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1397913","moleculeType":"Small molecule","molecularWeight":"339.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance administered in controlled clinical studies to serve as a comparator arm against the active investigational drug. It allows researchers to isolate the true therapeutic effect of the active agent by controlling for natural disease progression, regression to the mean, and patient expectation effects.","oneSentence":"This is a placebo control used in clinical trials and does not exert any active pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:27.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT05366855","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","status":"TERMINATED","sponsor":"Vanda Pharmaceuticals","startDate":"2022-04-21","conditions":"Generalized Pustular Psoriasis","enrollment":42},{"nctId":"NCT07498634","phase":"PHASE3","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","status":"COMPLETED","sponsor":"Zhejiang Kanova Biopharmaceutical Co., LTD","startDate":"2023-09-21","conditions":"Phase III","enrollment":323},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT05548556","phase":"PHASE2","title":"A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-02-07","conditions":"Facioscapulohumeral Muscular Dystrophy (FSHD)","enrollment":51},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT07441252","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-03-05","conditions":"Overweight or Obesity and Elevated Liver Fat","enrollment":180},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT06113328","phase":"PHASE2","title":"A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-27","conditions":"Non-segmental Vitiligo","enrollment":169},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT06641089","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","status":"RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":600},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":"NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis","enrollment":152},{"nctId":"NCT06878261","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT06883305","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT05595642","phase":"PHASE3","title":"A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-12-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1290},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07440524","phase":"PHASE2","title":"A Phase 2 Trial of JKN24011 in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":215},{"nctId":"NCT05037929","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-10-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1334},{"nctId":"NCT07074977","phase":"PHASE2","title":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","status":"RECRUITING","sponsor":"Galderma R&D","startDate":"2025-10-20","conditions":"Chronic Pruritus of Unknown Origin","enrollment":50},{"nctId":"NCT07356713","phase":"PHASE1","title":"A Study to Find a Suitable Dose of Exl-111 for Further Research","status":"RECRUITING","sponsor":"Excellergy Inc.","startDate":"2026-01-08","conditions":"Allergic Disease","enrollment":70},{"nctId":"NCT03157635","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-11-14","conditions":"Paroxysmal Hemoglobinuria, Nocturnal","enrollment":59},{"nctId":"NCT06106828","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-15","conditions":"Thyroid Eye Disease","enrollment":127},{"nctId":"NCT06280391","phase":"PHASE2","title":"A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2024-02-20","conditions":"Bronchiectasis","enrollment":312},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT06602258","phase":"PHASE2","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-09-30","conditions":"Alzheimer's Disease","enrollment":105},{"nctId":"NCT04895241","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-05-25","conditions":"Lupus Erythematosus, Systemic","enrollment":548},{"nctId":"NCT05987423","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-26","conditions":"Thyroid Eye Disease, TED","enrollment":131},{"nctId":"NCT04961567","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-07-16","conditions":"Lupus Erythematosus, Systemic","enrollment":562},{"nctId":"NCT07306585","phase":"PHASE1","title":"The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE","status":"NOT_YET_RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-12-30","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":32},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT07330310","phase":"PHASE3","title":"A Phase 3 Trial of JKN2401 Injection in COPD","status":"NOT_YET_RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":888},{"nctId":"NCT04266301","phase":"PHASE3","title":"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":530},{"nctId":"NCT03816891","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2019-03-11","conditions":"Prurigo Nodularis, Pruritis","enrollment":240},{"nctId":"NCT07230119","phase":"PHASE3","title":"A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)","status":"NOT_YET_RECRUITING","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","startDate":"2026-03-08","conditions":"Overweight , Obesity","enrollment":744},{"nctId":"NCT04090411","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-12-19","conditions":"Moderate to Severe Ulcerative Colitis","enrollment":246},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT07020884","phase":"PHASE2","title":"A Study of ZT002 Injection With Subjects With Overweight or Obesity","status":"COMPLETED","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","startDate":"2024-08-14","conditions":"Overweight or Obesity","enrollment":303},{"nctId":"NCT05516758","phase":"PHASE2","title":"A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2022-08-31","conditions":"Rheumatoid Arthritis, Arthritis, Joint Diseases","enrollment":491},{"nctId":"NCT05911841","phase":"PHASE2","title":"A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2023-06-21","conditions":"Atopic Dermatitis","enrollment":234},{"nctId":"NCT05724199","phase":"PHASE3","title":"A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-02-21","conditions":"Atopic Dermatitis","enrollment":746},{"nctId":"NCT05899816","phase":"PHASE3","title":"A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-06-07","conditions":"Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis","enrollment":221},{"nctId":"NCT05882877","phase":"PHASE3","title":"A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-05-31","conditions":"Atopic Dermatitis","enrollment":2621},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT05074433","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-10-25","conditions":"Immunocompromised","enrollment":66},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT03524092","phase":"PHASE3","title":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-19","conditions":"Ulcerative Colitis","enrollment":1177},{"nctId":"NCT04751487","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-02-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1239},{"nctId":"NCT04701983","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1127},{"nctId":"NCT05975905","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).","status":"COMPLETED","sponsor":"Keros Therapeutics, Inc.","startDate":"2023-10-17","conditions":"Pulmonary Arterial Hypertension","enrollment":113},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT07040930","phase":"PHASE1","title":"Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT04683029","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-02-24","conditions":"Scleroderma, Systemic","enrollment":56},{"nctId":"NCT04583423","phase":"PHASE2","title":"A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-11-11","conditions":"Nonalcoholic Steatohepatitis","enrollment":183},{"nctId":"NCT06208306","phase":"PHASE3","title":"A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":700},{"nctId":"NCT04365387","phase":"PHASE2","title":"A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-03-05","conditions":"Dermatitis, Atopic","enrollment":242},{"nctId":"NCT06118866","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Hope Medicine (Nanjing) Co., Ltd","startDate":"2023-09-11","conditions":"Androgenetic Alopecia","enrollment":192},{"nctId":"NCT06526182","phase":"PHASE3","title":"A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2024-07-03","conditions":"Dermatitis, Atopic, Eczema","enrollment":520},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT05651711","phase":"PHASE3","title":"A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-12-14","conditions":"Atopic Dermatitis","enrollment":726},{"nctId":"NCT04376827","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Lupus Nephritis","enrollment":33},{"nctId":"NCT03160885","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-06-12","conditions":"Atopic Dermatitis","enrollment":794},{"nctId":"NCT03131648","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-05-30","conditions":"Atopic Dermatitis","enrollment":802},{"nctId":"NCT04963270","phase":"PHASE3","title":"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-10-19","conditions":"Generalized Myasthenia Gravis","enrollment":188},{"nctId":"NCT04631016","phase":"PHASE2","title":"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-14","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis","enrollment":137},{"nctId":"NCT04039113","phase":"PHASE2","title":"Tezepelumab COPD Exacerbation Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-07-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":337},{"nctId":"NCT03792763","phase":"PHASE2","title":"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-09-30","conditions":"Multiple Myeloma","enrollment":8},{"nctId":"NCT06196203","phase":"PHASE2","title":"A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-02-07","conditions":"Higher-risk Myelodysplastic Syndromes","enrollment":90},{"nctId":"NCT01369355","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09-13","conditions":"Crohn's Disease, Colitis, IBD","enrollment":1282},{"nctId":"NCT03926130","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-23","conditions":"Crohn's Disease","enrollment":1158},{"nctId":"NCT06440746","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases","status":"RECRUITING","sponsor":"R-Pharm International, LLC","startDate":"2023-08-23","conditions":"Lung Diseases, Interstitial","enrollment":138},{"nctId":"NCT05324137","phase":"PHASE1, PHASE2","title":"A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-07-11","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":88},{"nctId":"NCT05052983","phase":"PHASE3","title":"A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-01-24","conditions":"Prurigo Nodularis","enrollment":34},{"nctId":"NCT05621070","phase":"PHASE3","title":"Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-03","conditions":"Primary Hypercholesterolaemia and Mixed Dyslipidemia","enrollment":582},{"nctId":"NCT03841448","phase":"PHASE2","title":"A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)","status":"TERMINATED","sponsor":"Alnylam Pharmaceuticals","startDate":"2019-09-30","conditions":"IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA","enrollment":31},{"nctId":"NCT04501666","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-09-11","conditions":"Prurigo Nodularis","enrollment":286},{"nctId":"NCT04501679","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-08-11","conditions":"Prurigo Nodularis","enrollment":274},{"nctId":"NCT05024058","phase":"PHASE3","title":"Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-16","conditions":"Chronic Inducible Urticaria","enrollment":39},{"nctId":"NCT05225857","phase":"PHASE1","title":"A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women","status":"COMPLETED","sponsor":"Angitia Biopharmaceuticals","startDate":"2022-06-28","conditions":"Osteoporosis","enrollment":90},{"nctId":"NCT05865496","phase":"PHASE2","title":"A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-06-30","conditions":"Sinusitis, Nasal Polyps, Polyps","enrollment":90},{"nctId":"NCT04797104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":478},{"nctId":"NCT04948554","phase":"PHASE1","title":"A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)","status":"TERMINATED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2023-03-10","conditions":"Systemic Sclerosis With and Without Interstitial Lung Disease","enrollment":5},{"nctId":"NCT02847598","phase":"PHASE2","title":"Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-10-20","conditions":"Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus","enrollment":264},{"nctId":"NCT05056779","phase":"PHASE3","title":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable","status":"WITHDRAWN","sponsor":"Galderma R&D","startDate":"2023-01","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":""},{"nctId":"NCT02760368","phase":"PHASE3","title":"Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-05-19","conditions":"Rheumatoid Arthritis","enrollment":428},{"nctId":"NCT02760433","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-01-25","conditions":"Rheumatoid Arthritis","enrollment":368},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT04760314","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-03-10","conditions":"Dermatitis, Atopic, Dermatitis, Eczema","enrollment":286},{"nctId":"NCT05062759","phase":"PHASE3","title":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Moderate to Severe Asthma","enrollment":70},{"nctId":"NCT05171348","phase":"PHASE1","title":"A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-01-07","conditions":"Asthma","enrollment":40},{"nctId":"NCT03533751","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AnaptysBio, Inc.","startDate":"2018-06-19","conditions":"Atopic Dermatitis","enrollment":302},{"nctId":"NCT04178967","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-10-29","conditions":"Atopic Dermatitis","enrollment":445},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo SC Q4W","genericName":"Placebo SC Q4W","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo SC Q4W is a placebo intervention used in a study to evaluate the safety and efficacy of CM326, a small molecule, in patients with various conditions including Chronic Rhinosinusitis With Nasal Polyps, Hypercholesterolaemia, Chronic Obstructive Pulmonary Disease, Anemia in Chronic Kidney Disease Patients Not on Dialysis, and Psoriasis. The study, CM326NP001, is a randomized, double-blind, placebo-controlled, dose escalation Phase 1b/2a study conducted by Keymed Biosciences Co.Ltd.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}